These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 2040587)

  • 1. Antibody reactivity to deletion mutants of the HIV-1 SF2 envelope.
    Back NK; Haigwood NL; de Wolf F; de Jongh BM; Goudsmit J
    Intervirology; 1991; 32(3):160-72. PubMed ID: 2040587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression.
    Zwart G; van der Hoek L; Valk M; Cornelissen MT; Baan E; Dekker J; Koot M; Kuiken CL; Goudsmit J
    Virology; 1994 Jun; 201(2):285-93. PubMed ID: 7514319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisera raised against the second variable region of the external envelope glycoprotein of human immunodeficiency virus type 1 cross-neutralize and show an increased neutralization index when they act together with antisera to the V3 neutralization epitope.
    Davis D; Stephens DM; Carne CA; Lachmann PJ
    J Gen Virol; 1993 Dec; 74 ( Pt 12)():2609-17. PubMed ID: 7506300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent and early HIV-1MN neutralizing capacity in sera from Dutch HIV-1 seroconverters is related to antibody reactivity to peptides from the gp120 V3 domain.
    Zwart G; Back NK; Ramautarsing C; Valk M; van der Hoek L; Goudsmit J
    AIDS Res Hum Retroviruses; 1994 Mar; 10(3):245-51. PubMed ID: 8018385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120.
    Liu F; Bergami PL; Duval M; Kuhrt D; Posner M; Cavacini L
    AIDS Res Hum Retroviruses; 2003 Jul; 19(7):597-607. PubMed ID: 12908937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the specificity of the human antibody response to the V3 neutralization domain of HIV-1.
    Zwart G; Wolfs TF; Valk M; Van der Hoek L; Kuiken CL; Goudsmit J
    AIDS Res Hum Retroviruses; 1992 Nov; 8(11):1897-908. PubMed ID: 1489578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fine specificity of antibody recognition may predict amino acid substitution in the third variable region of gp120 during HIV type 1 infection.
    Langedijk JP; Zwart G; Goudsmit J; Meloen RH
    AIDS Res Hum Retroviruses; 1995 Oct; 11(10):1153-62. PubMed ID: 8573370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A hidden region in the third variable domain of HIV-1 IIIB gp120 identified by a monoclonal antibody.
    Laman JD; Schellekens MM; Lewis GK; Moore JP; Matthews TJ; Langedijk JP; Meloen RH; Boersma WJ; Claassen E
    AIDS Res Hum Retroviruses; 1993 Jul; 9(7):605-12. PubMed ID: 8369165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of antibody assays for identifying and distinguishing recent from long-term HIV type 1 infection.
    Parekh BS; Pau CP; Kennedy MS; Dobbs TL; McDougal JS
    AIDS Res Hum Retroviruses; 2001 Jan; 17(2):137-46. PubMed ID: 11177393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contrasting IgA and IgG neutralization capacities and responses to HIV type 1 gp120 V3 loop in HIV-infected individuals.
    Kozlowski PA; Chen D; Eldridge JH; Jackson S
    AIDS Res Hum Retroviruses; 1994 Jul; 10(7):813-22. PubMed ID: 7986587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-idiotypic antibodies to the third variable domain of gp120 induce an anti-HIV-1 antibody response in mice.
    Boudet F; Theze J; Zouali M
    Virology; 1994 Apr; 200(1):176-88. PubMed ID: 7510435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
    Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
    J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.
    Young KR; Teal BE; Brooks Y; Green TD; Bower JF; Ross TM
    AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1259-68. PubMed ID: 15588348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies.
    Haigwood NL; Shuster JR; Moore GK; Lee H; Skiles PV; Higgins KW; Barr PJ; George-Nascimento C; Steimer KS
    AIDS Res Hum Retroviruses; 1990 Jul; 6(7):855-69. PubMed ID: 2390335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-reactivity of anti-HIV-1-p17-derivative peptide (P30-52) antibody to Env V3 peptide.
    Ota A; Tanaka-Taya K; Ueda S
    Hybridoma; 1999 Apr; 18(2):149-57. PubMed ID: 10380014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pattern of antibody response against the V3 loop in children with vertically acquired immunodeficiency virus type 1 (HIV-1) infection.
    De Rossi A; Zanotto C; Mammano F; Ometto L; Del Mistro A; Chieco-Bianchi L
    AIDS Res Hum Retroviruses; 1993 Mar; 9(3):221-8. PubMed ID: 7682425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of conformation on the neutralizing antibody response to HIV-1 gp120.
    Steimer KS; Haigwood NL
    Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.